Prostate Cancer

Our study establishes a clinically actionable amino acid metabolic signature and nomogram for PCa risk stratification, while suggesting FUS as a candidate therapeutic target. These findings bridge computational discovery with mechanistic validation, providing novel insights into the amino acid metabolic dependencies that govern prostate cancer (PCa) progression.

P1/2, N=6, Active, not recruiting, M.D. Anderson Cancer Center | N=36 --> 6 | Recruiting --> Active, not recruiting

P2, N=4, Completed, University Health Network, Toronto | Recruiting --> Completed | N=40 --> 4

P=N/A, N=1500, Recruiting, UMC Utrecht | Trial primary completion date: Feb 2023 --> Feb 2030

P=N/A, N=170, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P=N/A, N=270, Recruiting, Janssen Cilag S.A.S.

P=N/A, N=40, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting

P1, N=10, Completed, Eli Lilly and Company | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Jan 2026

P=N/A, N=8000, Recruiting, UMC Utrecht | Trial completion date: May 2025 --> Aug 2030 | Trial primary completion date: Feb 2024 --> Feb 2030

P=N/A, N=70, Recruiting, UMC Utrecht | Phase classification: P2 --> P=N/A | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027

P=N/A, N=80, Active, not recruiting, University of Oklahoma | Trial completion date: Feb 2025 --> Feb 2027

Finally, we discuss the predicted therapeutic approaches based on precision oncology to target and alter senescence using senolytics to eradicate aberrant senescent cells and senomorphics to target and adjust SASP. Addressing and regulating the plasticity of senescence is a significant and critical opportunity for improving the prognosis of prostate cancer, as well as guiding next-generation senescence-informed therapeutic approaches.